newsfilter
← Latest News
GlobeNewswire·

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative